Paul Donnellan

The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma

Louise E. Daly, Derek G. Power, Aine O’Reilly et al. · British Journal of Cancer · 2017 · 182 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Sandra M. Swain, Gong Tang, Charles E. Geyer et al. · Journal of Clinical Oncology · 2013 · 144 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries

Camillo Porta, Antonin Lévy, Robert D. Hawkins et al. · Cancer Medicine · 2014 · 61 citations · Full text

Medicine, Oncology, Pharmacology +16

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Madeleine King, Martin R. Stockler, Rachel O’Connell et al. · Quality of Life Research · 2017 · 58 citations

Medicine, Gynecology, Oncology +17